NCT04155190Phase 2Terminated

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Study sponsor: Sol-Gel Technologies, Ltd. · SLGL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-04-23Actual

Enrollment · participants50Actual

Source updated2026-07-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-11 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Number of New Surgically Eligible ~~BCCs~~ (nSEBs)

+ After

Measure: Number of Participants With New Surgically Eligible Basal Cell Carcinomas (nSEBs)

Check registry source